Evaluation Sub-Committee - Applications Considered
- 1353 – Measurement of Calprotectin as a marker of bowel inflammation
- 1372.1 – MRI of the liver for patients with colorectal carcinoma (CRC) with suspected hepatic metastases or patients with suspected hepatocellular carcinoma (HCC) for the purposes of staging
- 1376.1 – 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
- 1434 – Anti Mullerian hormone testing
- 1435 – Processing and cryopreservation of male and female gonadal tissue and gametes prior to or after gonadotoxic treatment to preserve fertility for the Future (Part B)
- 1449 – Genetic testing for Alport Syndrome
- 1460 – Blue Light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-invasive bladder cancer (NMIBC)
- 1466 – Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
- 1467 – Obstetric MRI
- 1475 – Ablative fractional laser resurfacing for burn scar treatment